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tions in the dysferlin (DYSF) gene. Dysferlin protein plays
a major role in plasma-membrane resealing. Some patients
withDYSF deletionmutations exhibit mild symptoms, suggest-
ing some regions ofDYSF can be removed without signiﬁcantly
impacting protein function. Antisense-mediated exon-skip-
ping therapy uses synthetic molecules called antisense oligonu-
cleotides to modulate splicing, allowing exons harboring or
near genetic mutations to be removed and the open reading
frame corrected. Previous studies have focused on DYSF exon
32 skipping as a potential therapeutic approach, based on the
association of a mild phenotype with the in-frame deletion of
exon 32. To date, no other DYSF exon-skipping targets have
been identiﬁed, and the relationship between DYSF exon dele-
tion pattern and protein function remains largely uncharacter-
ized. In this study, we utilized a membrane-wounding assay to
evaluate the ability of plasmid constructs carrying mutant
DYSF, as well as antisense oligonucleotides, to rescue mem-
brane resealing in patient cells. We report that multi-exon
skipping of DYSF exons 26–27 and 28–29 rescues plasma-
membrane resealing. Successful translation of these ﬁndings
into the development of clinical antisense drugs would estab-
lish new therapeutic approaches that would be applicable
to 5%–7% (exons 26–27 skipping) and 8% (exons 28–29
skipping) of dysferlinopathy patients worldwide.Received 9 July 2018; accepted 5 October 2018;
https://doi.org/10.1016/j.omtn.2018.10.004.
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The dysferlinopathies are a heterogeneous group of recessive myopa-
thies caused by mutations in the dysferlin (DYSF) gene.1,2 Character-
ized by progressive muscle weakness that typically begins during the
second decade of life, the dysferlinopathies can be clinically divided
into at least three types: Miyoshi myopathy (MM), limb-girdle
muscular dystrophy type 2B (LGMD2B), and distal myopathy with
anterior tibial onset (DMAT).1–3 The dysferlinopathies are clinically
distinguished based on the initial pattern of muscle weakness, origi-
nating in either the proximal (shoulder and pelvic girdle; LGMD2B)
or distal musculature (gastrocnemius and soleus; MM). The disease
can also present initially and often advances to include both the
proximal and distal muscles.4–6 While most patients experience a596 Molecular Therapy: Nucleic Acids Vol. 13 December 2018 ª 2018
This is an open access article under the CC BY-NC-ND license (httpgradual decline over decades, several atypical phenotypes have
been reported, including rapid loss of ambulation in less than 5 years.6
Variable age of onset has also been reported, ranging from 10 to
73 years.4,6,7
The DYSF gene codes for dysferlin protein, which is a large
(240 kDa) type II transmembrane protein containing seven lipid-
and protein-binding C2 domains, multiple Dysf and Fer domains,
and a C-terminal transmembrane domain8–16 (Figure 1). Dysferlin
is ubiquitously expressed but is most abundant in skeletal and cardiac
muscle.15,17 Dysferlin is predominantly localized to the plasma mem-
brane but is also observed in cytoplasmic vesicles and is associated
with the t-tubule network.15,17–20 Dysferlin protein plays an essential
role in plasma membrane repair, and loss of dysferlin results
in compromised membrane resealing and deterioration of muscle
ﬁbers.15,21,22 There is currently no cure for dysferlinopathy. Existing
disease management consists mainly of physical therapy, orthopaedic
surgery, and use of mechanical and respiratory aids.5,23
A promising therapeutic strategy that has gained traction in recent
years, especially with respect to neuromuscular disorders, is anti-
sense-mediated exon skipping. Exon skipping utilizes synthetic nu-
cleic acids called antisense oligonucleotides (AOs) to modulate pre-
mRNA splicing and can be used to remove mutation-carrying exons
and ﬂanking exons to maintain an open reading frame.24,25 In 2016,
the United States Food and Drug Administration (FDA) approved
eteplirsen (Exondys 51), the ﬁrst-ever antisense drug for the treat-
ment of Duchenne muscular dystrophy (DMD).26 Eteplirsen facili-
tates in-frame skipping of dystrophin exon 51 and utilizes the phos-
phorodiamidate morpholino oligomer (PMO) antisense chemistry.
The rationale for exon skipping in dysferlinopathy is supported by re-
ports of mildly affected patients harboring in-frame DYSF deletionThe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Human Dysferlin Domains Relative to Exons
There are 55 exons in the DYSF gene; dysferlin protein contains seven C2 domains (C2A–C2F), Ferlin family domains (F), an inner Dysf domain (D), and a second outer Dysf
domain (N- and C-terminal), and a transmembrane domain (T). Also depicted are putative binding sites for various dysferlin interacting proteins, such as AHNAK (AK),
Caveolin-3 (C), and Affixin (Beta-parvin; A). Predicted dysferlin domain positions and protein-protein interacting domains are based on coordinates available from the
Universal Mutation Database (http://www.umd.be/DYSF/W_DYSF/Protein.html) and from Wein et al.53
www.moleculartherapy.orgmutations, such as exon 32.27 Even large deletions of DYSF have been
associated with a milder disease course.28 Exon-skipping progress
in dysferlinopathy has been limited to the in vitro skipping of
DYSF exon 32 in human dysferlinopathy patient cells.29 To date, no
other therapeutic exon-skipping targets have been identiﬁed for
dysferlinopathy.
In this study, we undertook to identify novel exon-skipping targets
in DYSF by characterizing the relationship between exon-deletion
pattern and plasma-membrane-resealing ability. We created GFP-
conjugated DYSF plasmid constructs lacking certain exons and trans-
fected these into dysferlinopathy patient cells, then subjected the cells
to a membrane-wounding assay. We demonstrate that DYSF exon
combinations 19–21, 20–21, and 46–48 are required for proper
plasma-membrane resealing, while exons 26–27 and 28–29 are
dispensable for membrane resealing. After identifying which exons
were not required for proper membrane resealing, we designed
PMOs using a predictive software algorithm and tested the ability
of PMO cocktails to facilitate multi-exon skipping and restore mem-
brane-resealing ability in patient cells. We show that a PMO cocktail
targeting DYSF exons 28–29 restores membrane resealing in patient
cells. Our results provide a foundation for future in vivo investigations
and possible clinical translation ofDYSF exons 26–27 and 28–29 skip-
ping approaches for treating dysferlinopathy.
RESULTS
Mutation Analysis and Exon-Skipping Approach for
Dysferlinopathy Cell Lines
We ﬁrst assessed the mutation patterns present in two dysferlinop-
athy patient cell lines. The ﬁrst cell line, MM-Pt1, was originally
collected from a patient with MM. Sanger sequencing conﬁrmed a
homozygous missense mutation in DYSF exon 46 (Figure 2A). To re-
move the mutated exon while maintaining the reading frame would
involve multi-exon skipping ofDYSF exons 46–48 (Figure 2A). While
exons 46 and 47 do not code for any known protein domain, exon 48
codes for a portion of the C2F domain (Figure 2A). The second cell
line, MM-Pt2, was also collected from a patient with MM. Sanger
sequencing conﬁrmed that this cell line is transheterozygotic, carrying
a frameshift-causing point mutation in exon 21 on one allele and a
missense mutation in exon 28 on the other allele (Figure 2B). To re-
move the mutant exons while maintaining the reading frame would
involve double exon skipping of exons 20 and 21, or 28 and 29 (Fig-
ure 2B). Exons 20 and 21 do not code for any known protein domainof dysferlin, while exons 28 and 29 code for portions of the Dysf-N
and Dysf-C domains (Figure 2B).
Determining the Feasibility of Exon-Skipping Approaches in
Dysferlin through Transfection of Exon-Deleted Plasmid
Constructs
Before proceeding with the application of an exon-skipping approach
for our patient cell lines, we undertook to identify which DYSF exons
could be removed without negatively impacting protein function. To
do this, wemimicked the effect of exon skipping by using site-directed
mutagenesis to generate DYSF plasmid constructs lacking exons cor-
responding to an exon-skipping approach amenable to each cell line.
We generated GFP-fused DYSF plasmid constructs lacking DYSF
exons 20–21, 28–29, and 46–48, all of which are in-frame deletions.
We also generated an exon 19–21 deletion construct, as this pattern
of exon skipping would also restore the reading frame in MM-Pt2
(Figure 2B). Additionally, we generated an exon 26–27 deletion
construct, based on our later procurement of another dysferlinopathy
patient cell line harboring a c.2875C > T missense mutation in
exon 27. The deletion of DYSF exons 26–27 is in-frame (Figure 2B).
As a control, we generated a GFP-only plasmid. To identify whether
the exons deleted in the above constructs would have an impact
on protein function, we transfected the constructs into cell line
MM-Pt1, which exhibited impaired plasma-membrane-resealing
ability compared to healthy cells (Figure 3) and observed whether
any of these plasmids could rescue membrane-resealing ability. To
assess membrane-resealing ability, we incubated cells in FM4-64
dye and generated focal lesions in the plasma membranes of GFP-
positive cells using a two-photon laser microscope, as previously
described.21 FM4-64 dye quickly ﬂuoresces within the cytoplasm
upon entering the cell through the lesion, and membrane resealing
prevents entry of additional dye. We quantiﬁed the relative ﬂuores-
cence values of FM dye within the cytoplasm over time.30 Our results
show that D26–27 and D28–29 were able to rescue membrane-reseal-
ing ability to a degree similar to that of healthy cells and cells trans-
fected with the full-length DYSF plasmid, as measured by changes
in relative ﬂuorescence intensity over time (Figures 3A and 3B).
In contrast, D19–21, D20–21, and D46–48 were not able to rescue
membrane-resealing ability (Figures 3A and 3B).
We next considered that, while great care is taken to ensure that all
plasma-membrane-wounding parameters are consistent between ex-
periments (e.g., laser power, wavelength, number of iterations, etc.)Molecular Therapy: Nucleic Acids Vol. 13 December 2018 597
Figure 2. Dysferlinopathy Patient Cell Line Mutation Analysis
(A) Cell line MM-Pt1 was generated from a patient with Miyoshi myopathy and harbors a homozygous missense mutation in DYSF exon 46. (B) Cell line MM-Pt2 was
generated from a patient with Miyoshi myopathy and contains two mutations: a frameshift mutation in exon 21 on one allele and a missense mutation in exon 28 on the
second allele. Sanger sequencing was used to confirm the mutation patterns in both cell lines. Grey boxes represent exons, and ends of boxes denote corresponding
phasing; colored boxes below represent predicted protein domains.
Molecular Therapy: Nucleic Acidsthere can still be some disparity with respect to the degree of mem-
brane damage following laser ablation. This might generate some
small variation regarding quantiﬁcation, in terms of the amount of
ﬂuorescent dye which inﬁltrates the cell. We utilized an additional
measure of membrane-resealing ability, which we termed “time to
steady state,” deﬁning steady state as the point at which raw ﬂuores-
cence values peak following laser wounding without any signiﬁcant
increase over time (Figure 3C). Time to steady state is calculated by
subtracting the time prior to laser wounding from the time point
when ﬂuorescence values peak. We observed that the full-length as
well asD26–27 and D28–29 constructs were able to rescue membrane
resealing, as demonstrated by signiﬁcantly shorter times to steady
state when compared with GFP-only control; the D19–21, D20–21,
and D46–48 plasmid constructs were not able to rescue membrane
resealing, as their times to steady state were not statistically different
from GFP-only control (Figure 3D). Taken together, these
results show that DYSF exons 26–27 and 28–29 are dispensable
for plasma-membrane resealing, suggesting that these exons are
promising therapeutic targets for exon skipping, while exons 19–21,
20–21, and 46–48 are required for proper membrane resealing, sug-
gesting that these are not promising exon-skipping targets.
In Silico and In Vitro Screening of PMOs for DYSF Exon 28–29
Skipping
Our exon-skipping predictive algorithm31 projected the expected
exon-skipping efﬁciencies for 191 PMO sequences of 30-mer length,
covering all possible target sites for exons 28 and 29. From these, the
top three PMO sequences with the highest predicted exon-skipping598 Molecular Therapy: Nucleic Acids Vol. 13 December 2018efﬁciency that also met synthesis criteria (e.g., GC content, melting
temperature [Tm], self-complementarity) were selected by us and
produced by GeneTools (Philomath, Oregon) (Table 1). As measured
by RT-PCR, all nine possible combinations of PMO cocktails were
able to efﬁciently skip DYSF exons 28 and 29 using 10 mM each oligo
in MM-Pt2 cells, suggesting that substantive multiple exon skipping
can be achieved in DYSF through the use of PMO cocktails (Fig-
ure 4A). To examine rescue of dysferlin protein, we performed west-
ern blot analysis and found that there was no detectable change in
protein levels between control and 10 mM each oligo treatment
groups, while mutant cells also expressed detectable levels of dysferlin
(Figure 4B).
Rescue of Plasma-Membrane Resealing in PMO Cocktail-
Treated Dysferlinopathy Patient Cells
We selected PMO cocktail Ac11+32, which showed a high degree of
DYSF exon 28–29 skipping, as measured by RT-PCR (Figure 4A), for
transfection into patient cells (MM-Pt2). We observed that Ac11+32
was able to rescue plasma membrane resealing in dysferlinopathy
patient ﬁbroblasts, as measured by changes in relative ﬂuorescence
intensity over time (Figures 5A and 5B). Ac11+32 was also able to
signiﬁcantly reduce the time to membrane resealing, as measured
by time to steady state (Figure 5C). These results show that functional
recovery of membrane wounding in vitro is possible through anti-
sense-mediated exon skipping of DYSF exons 28–29 via PMO cock-
tail, suggesting that these PMOs might be promising therapeutic
agents for treating patients with mutations amenable to DYSF exon
28–29 skipping.
Figure 3. Transfection with D26–27 or D28–29 DYSF
Plasmid Restores Membrane Resealing Ability in
Dysferlinopathy Patient Cells
(A) A membrane-wounding assay was performed on dys-
ferlinopathy patient cells (MM-Pt1) transfected with various
plasmids. Relative fluorescence intensity (DF/F0) over time
is shown asmeans± SE. (B) Graphical representation of (A)
showing relative fluorescence intensity at final time point
(t = 300 s). (C) Representative image of raw fluorescence
values over time generated bymembranewounding assay.
Line with double arrows depicts the final time point from
which fluorescence values no longer significantly increase
over time. Blue bar represents the time from laser
wounding until the time point when fluorescence values
peak, termed “steady state.” (D) Graphical representation
of steady-state means ± SE. Statistics, one-way ANOVA
and Tukey-Kramer multiple comparisons test. **p < 0.005,
***p < 0.0005, ****p < 0.0001 compared to GFP-only.
www.moleculartherapy.orgDISCUSSION
The ﬁrst identiﬁcation of a potential therapeutic exon skipping target in
dysferlinopathy was DYSF exon 32, described by Sinnreich et al.27 in
2006. Since then, no new therapeutic exon-skipping targets have been
described for DYSF. While some groups have attempted to identify
redundant protein domains for the purpose of mini- or nano-dysferlin
delivery via AAV vector,32 the relationship between exon-deletion
pattern and protein functionality has gone largely uncharacterized. In
this report, we described not only the ﬁrst-ever success of multiple
exon skipping inDYSF, but also the identiﬁcation of twonovel potential
therapeutic exon-skipping targets for treating dysferlinopathy—DYSF
exon 26–27 and 28–29 skipping. Notably,DYSF exons 26–29 were pre-
sent in previously used nano-dysferlin constructs but not in mini-dys-
ferlin constructs, both of which were able to ameliorate pathology and
membrane-resealing defects in dysferlinopathy mouse models.32,33
Successful translation of these ﬁndings into the development of clinical
AO drugs would establish new therapeutic approaches that, combined,
would be applicable to approximately 5%–7% (exon 26–27 skipping)
and 8% (exon 28–29 skipping) of dysferlinopathy patients worldwide,
according to reported variant data in the Leiden Open Variation Data-
base (LOVD) (http://www.dmd.nl/) and Universal Mutation Database
(UMD) (http://www.umd.be/DYSF/) (Figure 6).
This work further supports the use of dysferlinopathy patient
ﬁbroblasts in screening novel AO sequences for the identiﬁcation of
therapeutic exon-skipping drugs, as ﬁbroblasts expressed readily
detectable amounts of DYSF mRNA at levels sufﬁcient for in vitro
assessment of exon-skipping efﬁciencies. While our AO sequences
were able to facilitate robust exon skipping in ﬁbroblasts, it remains
to be seen whether the same sequences will be comparably effective
when transfected into muscle cells and in vivo.Molecular TheraOur study also further validates the use of dys-
ferlinopathy ﬁbroblasts as an effective alterna-
tive to myoblasts or myotubes for the purposeof assessing plasma-membrane repair.30,34 Here, healthy and dysfer-
linopathy patient ﬁbroblasts displayed signiﬁcant differences in their
ability to reseal plasma membranes following two-photon laser
wounding. Furthermore, this study highlights how the membrane-
wounding assay can be used to validate the in vitro effectiveness of
newly designed AOs at rescuing dysferlin protein function.
Since as little as 10% of wild-type protein has been associated with
very mild pathology in dysferlinopathy27 and our cell line MM-Pt2
expresses dysferlin protein somewhere between 25% and 50% of
wild-type (Figure 4B), it is reasonable to assume that while the endog-
enous missense mutation may not affect protein stability, there is an
appreciable effect on protein functionality, as evidenced here by the
signiﬁcant difference in membrane-resealing ability between healthy
and patient cells. The observation that our PMO cocktail was able to
rescue plasma membrane resealing in patient cells despite no differ-
ence in protein expression between treated and non-treated cells is
consistent with the idea that the proteins produced here via exon skip-
ping could be more functional than non-treated proteins. Future
studies aimed at characterizing the intracellular differences between
native and exon-skipped proteins, such as their respective subcellular
localization and interaction with other proteins, will help shed light
on this issue. It would also be beneﬁcial to test our PMO cocktail
in a DYSF-null cell line with a mutation pattern amenable to exon
28–29 skipping in order to determine the degree of protein rescue
following transfection.
The human dysferlin Dysf domains contain multiple positively
charged and aromatic residues that exhibit a high degree of conserva-
tion in comparison to ferlin homologs myoferlin and fer-1.16 The sec-
ondary structure of the human inner Dysf domain consists of twopy: Nucleic Acids Vol. 13 December 2018 599
Table 1. Selected PMO Sequences for DYSF Exon 28–29 Skipping
DYSF Exon to Skip Oligo Name Distance from Acceptor Splice Site Oligo Sequence (50 to 30) Predicted Skip (%)
28 Ac7 7 ACTCAATGTCATCCTTGGGAAGCACCTTCT 70.52
28 Ac11 11 GGGCACTCAATGTCATCCTTGGGAAGCACC 68.21
28 Ac41 41 CATTCCTCATCTTCCCACTTCCAGCCCAGT 61.01
29 Ac36 36 TCTTCTCAGCAGGGACCCAGTGCTTCGGCT 86.38
29 Ac32 32 CTCAGCAGGGACCCAGTGCTTCGGCTTCCG 79.7
29 Ac40 40 TACATCTTCTCAGCAGGGACCCAGTGCTTC 62.06
Molecular Therapy: Nucleic Acidsantiparallel b strands, one at each terminus.35 This secondary struc-
ture is conserved in the inner Dysf domain of myoferlin.36 The solu-
tion structure of the myoferlin Dysf domain indicates the presence of
stacked tryptophan/arginine (W/R) motifs, and mutations in this re-
gion are predicted to result in unfolding and protein degradation.36
Like myoferlin, the dysferlin inner Dysf domain is also held together
by stacking of arginine and aromatic sidechains, and disruption of
this region is also predicted to result in instability and unfolding.35
Notably, the majority of residues of this ﬂat domain region contribute
to the surface, suggesting that perhaps the Dysf domain is involved in
protein-protein interactions.35 While this region is evidently suscep-
tible to deleterious mutations according to the LOVD database,37 our
demonstration that removal of exons 26–27 and 28–29 does not
impact dysferlin protein function suggests that removal of portions
of the Dysf domains is a possible therapeutic strategy. The hypothesisFigure 4. PMO Cocktails Facilitate Multi-exon Skipping of DYSF Exons 28–29 i
All transfections were performed using 10 mM each PMO. (A) Efficiency of exon 28–29 sk
marker. Values are shown asmean ±SE (n = 3). Statistics, one-way ANOVA and Tukey-K
blot assessment of dysferlin protein expression following PMO cocktail transfection, wi
600 Molecular Therapy: Nucleic Acids Vol. 13 December 2018that this region of dysferlin may be superﬂuous is supported by the
use of a mini-dysferlin that does not contain the Dysf domain but
is able to rescue membrane resealing and dysferlin expression in a
mouse model of dysferlinopathy.33
While dysferlin is known to have several binding partners,38–41 the
most likely interacting partner at the Dysf domains is caveolin-3
(CAV-3).13,42 Mutations in CAV-3 are implicated in several forms
of muscular dystrophy.43–45 CAV-3 is the only caveolin family mem-
ber expressed in striated muscle and belongs to the dystrophin-glyco-
protein complex, forming scaffolding along with t-tubules and caveo-
lar membranes.46–48 CAV-3 is expressed primarily in muscle, where it
plays a role in regulating sarcolemma stability, vesicular trafﬁcking,
signal transduction, and regulation of nitric-oxide-dependent func-
tions.49–52 Importantly, there exist two putative CAV-3 binding sitesn Patient Cells
ipping as measured by one-step RT-PCR. Representative image shown. M, 100 bp
ramer multiple comparisons test. *p < 0.0001 compared to non-treated. (B)Western
th alpha-tubulin as a loading control.
Figure 5. Antisense-Mediated Skipping of DYSF
Exons 28–29 via PMO Cocktail Rescues Membrane
Resealing Ability in Dysferlinopathy Patient Cells
(A) Dysferlinopathy patient cells (MM-Pt2) transfected with
PMO cocktail. Relative fluorescence intensity (DF/F0) over
time is shown asmeans ± SE. (B) Graphical representation
of (A) showing relative fluorescence intensity at the final
time point (t = 300 s). (C) Graphical representation of time
to steady state, means ± SE. Statistics, one-way
ANOVA and Tukey-Kramer multiple comparisons test.
***p < 0.0005, ****p < 0.0001 compared to mock treated.
www.moleculartherapy.orgwithin the Dysf domains of dysferlin, with one found in the region of
exons 25–26 and the other in the region of exons 28–29 (Figure 1).53
An additional CAV-3 binding site is located in a region that corre-
sponds to exon 6. Our analyses were performed in ﬁbroblasts, ruling
out interactions with CAV-3 as inﬂuencing membrane resealing in
this setting; however, it may be worth investigating possible Dysf
domain and CAV-3 interactions in muscle cells.
It is also worth noting that patients with the exon 28 c.2997G > T
missensemutation are reported to have signiﬁcantly later disease onset
(32.2 ± 4.8 years), and a patient homozygous for the c.2997G > T mu-
tation did not use a cane at age 46.54,55 Our results further underscore
the therapeutic potential of aDYSF exon 28–29 skipping approach and
suggest that whatever unknown function(s) the dysferlinDysf domains
serve, they are either not directly related to the process of plasma-mem-
brane resealing or their function is redundant.
In conclusion, this study represents a signiﬁcant achievement in the
development of novel therapeutic strategies for treating dysferlinop-
athy. There are currently no ongoing or planned clinical trials involving
exon skipping for dysferlinopathy, despite the successful translation
of exon-skipping therapy into several clinical trials for other
forms of muscular dystrophy, such as DMD (see ClinicalTrials.gov:
NCT02958202, NCT02667483, NCT03375255, and NCT03167255).
Our identiﬁcation of two novel exon-skipping targets in vitro paves
the way for future in vivo work that will help establish a foundation
for the future clinical implementation of antisense-mediated exon
skipping in dysferlinopathy.
MATERIALS AND METHODS
Cell Culture
Human dysferlinopathy patient ﬁbroblast cells harboring trans-het-
erozygous c.1958delG/c.2997G > T mutations (ID, MM-Pt2) and
ﬁbroblast cells harboring a homozygous c.5077C > T mutation (ID,Molecular TheraMM-Pt1) were obtained from the induced
pluripotent stem cell (iPSC) bank at Kyoto
University. Healthy human ﬁbroblasts (ID,
GM23815) were obtained from the Coriell Insti-
tute for Medical Research (Camden, NJ, USA).
Fibroblast cells were cultured in DMEM/F-12growthmedia (Invitrogen, Carlsbad, CA) containing 10% fetal bovine
serum (FBS) and 0.5% penicillin and streptomycin and incubated in a
CO2 incubator at 37C.
Plasmid Construct Design and Transfection
A plasmid construct containing N-terminally GFP-tagged DYSF
(termed full-length DYSF plasmid) was generously provided by
Dr. Katherine Bushby (Newcastle University). All other DYSF
plasmid constructs investigated in this study (D19–21, D20–21,
D26–27, D28–29, D46–48, GFP-only) were generated using a Q5
Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA)
according to manufacturer’s instructions (for primers, see Table 2).
Plasmid constructs were transfected into cells using a Lipofectamine
LTX with Plus Reagent kit (Thermo Fisher) according to manufac-
turer’s instructions. In brief, ﬁbroblast cells were seeded into
35-mm collagen-coated glass-bottom dishes (MatTek, Ashland,
MA) and cultured in 2 mL of growth media for 24 hr. After incuba-
tion, media was changed to 2.3 mL of Opti-MEM (Thermo Fisher)
containing 3 mL Lipofectamine LTX Transfection Reagent, 3.5 mL
of PLUS Reagent, and 3.5 mg of plasmid. Cells were then incubated
for 24 hr, after which media was changed to fresh growth media
and cells were incubated an additional 24 hr before imaging and
membrane-wounding analysis.
PMO Design and Transfection
PMO sequences targeting DYSF exons were designed using a predic-
tive software tool designed by our group that estimates expected
exon-skipping efﬁciency.31 The top three PMOs per exon with the
highest predicted exon-skipping ability and that met technical criteria
for synthesis (e.g., GC content, Tm, self-complementarity) were sup-
plied by Gene Tools (Philomath, Oregon). PMO sequences are shown
in Table 1. For molecular analysis, PMO cocktails were transfected
into 70%–80% conﬂuent patient ﬁbroblast cells using 6 mM Endo-
Porter (Gene Tools) transfection reagent at a ﬁnal concentration ofpy: Nucleic Acids Vol. 13 December 2018 601
Figure 6. Projected Therapeutic Applicability ofDYSFExon 28–29 and 26–27
Skipping
Potential therapeutic applicability of DYSF exons 28–29 and 26–27 skipping is
based on mutation variants reported in the Leiden Open Variation Database (LOVD)
and Universal Mutation Database (UMD). Applicability was calculated by taking the
number of reported variants withinDYSF exons 28–29 (116 in LOVD and 97 in UMD)
or 26–27 (94 in LOVD and 57 in UMD) and dividing by the total number of reported
individuals with variants (1,332 total reported in LOVD and 1,174 total reported in
UMD). LOVD data was obtained in May 2018, and UMD data available in May 2018
was taken from UMD-DYSF v1.4 data from June 16, 2015.
Table 2. Primers Used in Site-Directed Mutagenesis and PCR
Primer Name Primer Sequence (50 to 30)
Site-Directed Mutagenesis
hDYSF DSC-B GFP REV CTACTACTTGTACAGCTCGTCCATGC
hDYSF DSC-B GFP FWD GGCCGCTCGAGTCTAGAGGG
hDYSF DSC-B Ex49 FWD GTTTTTCCTGCGTTGTATTATC
hDYSF DSC-B Ex45 REV ACACAGTAGGTCTGTGGG
hDYSF DSC-B Ex22 FWD GAAGCTGGCCTGGAGCAG
hDYSF DSC-B Ex18 REV CTTGCCTGTGTTGAGCTCTG
hDYSF DSC-B Ex19 REV CTCCACCCGGAGGATGTC
hDYSF DSC-B Ex28 FWD AACGGGGAGAAGGTGCTT
hDYSF DSC-B Ex25 REV GGTTTCAGCAAAGACAGACAG
hDYSF DSC-B Ex30 FWD CACAGGCAGGCGGAGGCG
hDYSF DSC-B Ex27 REV CACATCGGTGTAGTTGTCACTCATGTAGATCC
RT-PCR
hDYSF Ex26 FWD CGAGACTAAGTTGGCCCTTG
hDYSF Ex30 REV GGCATCTGTCTTGCGGTACT
Molecular Therapy: Nucleic Acids10 mM each PMO in DMEM (Invitrogen). Cells were incubated in
PMOs for 48 hr before harvesting. For the two-photon membrane-
wounding assay, 40%–50% conﬂuent patient ﬁbroblast cells were
incubated with PMO in growthmedia for 48 hr before being subjected
to the wounding assay.
RT-PCR Analysis
Total RNA was extracted from cells using Trizol (Invitrogen), and
200 ng of total RNA was used for assessing exon-skipping efﬁciency
via SuperScript III One-Step RT-PCR System with Platinum Taq
DNA Polymerase (Invitrogen). Primers are shown in Table 2.
RT-PCR conditions are as follows: 1, 50C (20 min); 2, 94C
(2 min); 3, 94C (15 s); 4, 63C (30 s); 5, 68C (37 s); 6, go to 3, repeat
35; 7, 68C (5 min). PCR products were electrophoresed on a
1.5% agarose gel, and bands of interest were excised using PureLink
Quick Gel Extraction Kit (Invitrogen) and sequenced via Sanger
sequencing.
Immunoblotting
1.5 mg of protein from PMO-treated MM-Pt2 ﬁbroblasts were loaded
onto a NuPAGE Novex 3%–8% Tris-Acetate Midi Gel (Invitrogen)
and separated by SDS-PAGE at 150 V for 70 min. Proteins were
transferred onto an Immobilon polyvinylidene ﬂuoride (PVDF)
membrane (MilliporeSigma, Darmstadt, Germany) by semidry blot-
ting using 20 V for 45 min. The membrane was blocked with PBS
containing 0.05% Tween 20 and 5% skimmed milk, then incubated
with the NCL Hamlet monoclonal antibody (Leica Biosystems,
Wetzlar, Germany; 1:4,000 in blocking solution) or alpha-tubulin
ab7291 antibody (Abcam, Cambridge, UK; 1:8,000 in blocking602 Molecular Therapy: Nucleic Acids Vol. 13 December 2018solution) at 4C overnight. Membranes were then incubated with
1:10,000 goat anti-mouse immunoglobulin G (IgG) (H+L) secondary
antibody, horseradish peroxidase (HRP) (Thermo Fisher), followed
by incubation with ECL Select (GE Healthcare, Little Chalfont,
UK). Bands were detected using a ChemiDoc system (Bio-Rad,
Hercules, CA).
Membrane-Wounding Assay
Human ﬁbroblast plasmamembranes were subjected to laser-induced
injury using two-photon laser microscopy as described previously.30
In brief, cells in glass-bottom dishes were prepared for wounding by
rinsing once with Tyrode’s salts solution (MilliporeSigma) followed
by addition of 1 mL of Tyrode’s salts containing 2.5 mM FM4-64
dye (Invitrogen). Only GFP-positive cells were selected for mem-
brane-wounding experiments. A minimum of 15 cells were wounded
per treatment. Using a Zeiss LSM 710 inverted confocal laser scanning
microscope and Zeiss ZEN software, a 0.2 mm  2 mm target was
placed at the edge of the cellmembrane. A 5-min time series of sequen-
tial image scans was performed, with cells imaged every 5 s. Cells were
ablated 25 s after the beginning of the time series using a two-photon
laser set to 820 nm, using 15% laser power with 10 iterations. Fluores-
cence values at sites of injury were quantiﬁed using Zeiss ZEN soft-
ware, and for each time point relative ﬂuorescence values were deter-
mined by subtraction of the background value (mean of t = 0–25 s) and
division of the net increase in ﬂuorescence by the background ﬂuores-
cence value.
Statistical Analysis
All data were reported as mean values ± SE. The statistical differences
between treatment groups were assessed by one-way ANOVA with a
Tukey-Kramer multiple comparison test. p < 0.05 was considered sta-
tistically signiﬁcant.
www.moleculartherapy.orgAUTHOR CONTRIBUTIONS
Conceptualization of Experiments, T.Y.; Investigation, J.J.A.L.;
Formal Analysis, J.J.A.L., R.M., T.Y.; Supervision, R.M., T.Y.;
Software, W.D.; Provision of Materials/Samples, H.S.; Writing:
J.J.A.L., T.Y.
CONFLICTS OF INTEREST
The authors declare no competing interests.
ACKNOWLEDGMENTS
This work was supported by the University of Alberta Faculty of
Medicine and Dentistry, The Friends of Garrett Cumming Research
Chair Fund, the HM Toupin Neurological Science Research Chair
Fund, Muscular Dystrophy Canada, the Canada Foundation for
Innovation (CFI), Alberta Advanced Education and Technology
(AET), the Canadian Institutes of Health Research (CIHR), Jesse’s
Journey - The Foundation for Gene and Cell Therapy, the Women
and Children’s Health Research Institute (WCHRI), Alberta Inno-
vates Health Solutions (AIHS), The Rare Disease Foundation, and
the BC Children’s Hospital Foundation. We thank Dr. Katherine
Bushby for supplying us with the full-length DYSF plasmid. We
would also like to thank Dr. Katsuya Miyake for technical advice.
REFERENCES
1. Liu, J., Aoki, M., Illa, I., Wu, C., Fardeau, M., Angelini, C., Serrano, C., Urtizberea,
J.A., Hentati, F., Hamida, M.B., et al. (1998). Dysferlin, a novel skeletal muscle
gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat.
Genet. 20, 31–36.
2. Bashir, R., Britton, S., Strachan, T., Keers, S., Vaﬁadaki, E., Lako, M., Richard, I.,
Marchand, S., Bourg, N., Argov, Z., et al. (1998). A gene related to Caenorhabditis
elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy
type 2B. Nat. Genet. 20, 37–42.
3. Illa, I., Serrano-Munuera, C., Gallardo, E., Lasa, A., Rojas-García, R., Palmer, J.,
Gallano, P., Baiget, M., Matsuda, C., and Brown, R.H. (2001). Distal anterior
compartment myopathy: a dysferlin mutation causing a new muscular dystrophy
phenotype. Ann. Neurol. 49, 130–134.
4. Klinge, L., Dean, A.F., Kress, W., Dixon, P., Charlton, R., Müller, J.S., Anderson, L.V.,
Straub, V., Barresi, R., Lochmüller, H., and Bushby, K. (2008). Late onset in dysfer-
linopathy widens the clinical spectrum. Neuromuscul. Disord. 18, 288–290.
5. Aoki, M. (1993). Dysferlinopathy. In GeneReviews, M.P. Adam, H.H. Ardinger, R.A.
Pagon, and S.E. Wallace, eds. (University of Washington, Seattle).
6. Nguyen, K., Bassez, G., Krahn, M., Bernard, R., Laforêt, P., Labelle, V., Urtizberea,
J.A., Figarella-Branger, D., Romero, N., Attarian, S., et al. (2007). Phenotypic study
in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.
Arch. Neurol. 64, 1176–1182.
7. Jethwa, H., Jacques, T.S., Gunny, R., Wedderburn, L.R., Pilkington, C., and Manzur,
A.Y. (2013). Limb girdle muscular dystrophy type 2B masquerading as inﬂammatory
myopathy: case report. Pediatr. Rheumatol. Online J. 11, 19.
8. Therrien, C., Di Fulvio, S., Pickles, S., and Sinnreich, M. (2009). Characterization of
lipid binding speciﬁcities of dysferlin C2 domains reveals novel interactions with
phosphoinositides. Biochemistry 48, 2377–2384.
9. Davis, D.B., Doherty, K.R., Delmonte, A.J., and McNally, E.M. (2002). Calcium-sen-
sitive phospholipid binding properties of normal and mutant ferlin C2 domains.
J. Biol. Chem. 277, 22883–22888.
10. Lennon, N.J., Kho, A., Bacskai, B.J., Perlmutter, S.L., Hyman, B.T., and Brown, R.H.,
Jr. (2003). Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal
wound-healing. J. Biol. Chem. 278, 50466–50473.11. Azakir, B.A., Di Fulvio, S., Therrien, C., and Sinnreich, M. (2010). Dysferlin interacts
with tubulin and microtubules in mouse skeletal muscle. PLoS ONE 5, e10122.
12. Cai, C., Weisleder, N., Ko, J.K., Komazaki, S., Sunada, Y., Nishi, M., Takeshima, H.,
and Ma, J. (2009). Membrane repair defects in muscular dystrophy are linked to
altered interaction between MG53, caveolin-3, and dysferlin. J. Biol. Chem. 284,
15894–15902.
13. Matsuda, C., Hayashi, Y.K., Ogawa, M., Aoki, M., Murayama, K., Nishino, I., Nonaka,
I., Arahata, K., and Brown, R.H., Jr. (2001). The sarcolemmal proteins dysferlin and
caveolin-3 interact in skeletal muscle. Hum. Mol. Genet. 10, 1761–1766.
14. Huang, Y., Laval, S.H., van Remoortere, A., Baudier, J., Benaud, C., Anderson, L.V.,
Straub, V., Deelder, A., Frants, R.R., den Dunnen, J.T., et al. (2007). AHNAK, a novel
component of the dysferlin protein complex, redistributes to the cytoplasm with dys-
ferlin during skeletal muscle regeneration. FASEB J. 21, 732–742.
15. Bansal, D., and Campbell, K.P. (2004). Dysferlin and the plasma membrane repair in
muscular dystrophy. Trends Cell Biol. 14, 206–213.
16. Therrien, C., Dodig, D., Karpati, G., and Sinnreich, M. (2006). Mutation impact on
dysferlin inferred from database analysis and computer-based structural predictions.
J. Neurol. Sci. 250, 71–78.
17. Anderson, L.V., Davison, K., Moss, J.A., Young, C., Cullen, M.J., Walsh, J., Johnson,
M.A., Bashir, R., Britton, S., Keers, S., et al. (1999). Dysferlin is a plasma membrane
protein and is expressed early in human development. Hum. Mol. Genet. 8, 855–861.
18. Piccolo, F., Moore, S.A., Ford, G.C., and Campbell, K.P. (2000). Intracellular accumu-
lation and reduced sarcolemmal expression of dysferlin in limb—girdle muscular
dystrophies. Ann. Neurol. 48, 902–912.
19. Kerr, J.P., Ziman, A.P., Mueller, A.L., Muriel, J.M., Kleinhans-Welte, E., Gumerson,
J.D., Vogel, S.S., Ward, C.W., Roche, J.A., and Bloch, R.J. (2013). Dysferlin stabilizes
stress-induced Ca2+ signaling in the transverse tubule membrane. Proc. Natl. Acad.
Sci. USA 110, 20831–20836.
20. Klinge, L., Laval, S., Keers, S., Haldane, F., Straub, V., Barresi, R., and Bushby, K.
(2007). From T-tubule to sarcolemma: damage-induced dysferlin translocation in
early myogenesis. FASEB J. 21, 1768–1776.
21. Bansal, D., Miyake, K., Vogel, S.S., Groh, S., Chen, C.C., Williamson, R., McNeil, P.L.,
and Campbell, K.P. (2003). Defective membrane repair in dysferlin-deﬁcient
muscular dystrophy. Nature 423, 168–172.
22. Roche, J.A., Lovering, R.M., Roche, R., Ru, L.W., Reed, P.W., and Bloch, R.J. (2010).
Extensive mononuclear inﬁltration and myogenesis characterize recovery of dysfer-
lin-null skeletal muscle from contraction-induced injuries. Am. J. Physiol. Cell
Physiol. 298, C298–C312.
23. Kobayashi, K., Izawa, T., Kuwamura, M., and Yamate, J. (2012). Dysferlin and animal
models for dysferlinopathy. J. Toxicol. Pathol. 25, 135–147.
24. Lee, J.J., and Yokota, T. (2013). Antisense therapy in neurology. J. Pers. Med. 3,
144–176.
25. Niks, E.H., and Aartsma-Rus, A. (2017). Exon skipping: a ﬁrst in class strategy for
Duchenne muscular dystrophy. Expert Opin. Biol. Ther. 17, 225–236.
26. Aartsma-Rus, A., and Krieg, A.M. (2017). FDA Approves Eteplirsen for Duchenne
Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther.
27, 1–3.
27. Sinnreich, M., Therrien, C., and Karpati, G. (2006). Lariat branch point mutation in
the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66, 1114–
1116.
28. Krahn, M., Wein, N., Lostal, W., Bourg-Alibert, N., Nguyen, K., Courrier, S., Vial, C.,
Labelle, V., De Petris, D., Borges, A., et al. (2008). G.O.5 Partial functionality of a
Mini-dysferlin molecule identiﬁed in a patient affected with moderately severe pri-
mary dysferlinopathy. Neuromuscul. Disord. 18, 781.
29. Barthélémy, F., Blouin, C., Wein, N., Mouly, V., Courrier, S., Dionnet, E., Kergourlay,
V., Mathieu, Y., Garcia, L., Butler-Browne, G., et al. (2015). Exon 32 Skipping of
Dysferlin Rescues Membrane Repair in Patients’ Cells. J. Neuromuscul. Dis. 2,
281–290.
30. Lee, J.J.A., Maruyama, R., Sakurai, H., and Yokota, T. (2018). Cell Membrane Repair
Assay Using a Two-photon Laser Microscope. J. Vis. Exp. 131, e56999.Molecular Therapy: Nucleic Acids Vol. 13 December 2018 603
Molecular Therapy: Nucleic Acids31. Echigoya, Y., Mouly, V., Garcia, L., Yokota, T., and Duddy, W. (2015). In silico
screening based on predictive algorithms as a design tool for exon skipping oligonu-
cleotides in Duchenne muscular dystrophy. PLoS ONE 10, e0120058.
32. Llanga, T., Nagy, N., Conatser, L., Dial, C., Sutton, R.B., and Hirsch, M.L. (2017).
Structure-Based Designed Nano-Dysferlin Signiﬁcantly Improves Dysferlinopathy
in BLA/J Mice. Mol. Ther. 25, 2150–2162.
33. Krahn, M., Wein, N., Bartoli, M., Lostal, W., Courrier, S., Bourg-Alibert, N., Nguyen,
K., Vial, C., Streichenberger, N., Labelle, V., et al. (2010). A naturally occurring
human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dys-
ferlinopathy. Sci. Transl. Med. 2, 50ra69.
34. Matsuda, C., Kiyosue, K., Nishino, I., Goto, Y., and Hayashi, Y.K. (2015).
Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair. PLoS
Curr. 7, ecurrents.md.5865add2d766f39a0e0411d38a7ba09c.
35. Sula, A., Cole, A.R., Yeats, C., Orengo, C., and Keep, N.H. (2014). Crystal structures of
the human Dysferlin inner DysF domain. BMC Struct. Biol. 14, 3.
36. Patel, P., Harris, R., Geddes, S.M., Strehle, E.M., Watson, J.D., Bashir, R., Bushby, K.,
Driscoll, P.C., and Keep, N.H. (2008). Solution structure of the inner DysF domain of
myoferlin and implications for limb girdle muscular dystrophy type 2b. J. Mol. Biol.
379, 981–990.
37. Fokkema, I.F., Taschner, P.E., Schaafsma, G.C., Celli, J., Laros, J.F., and den Dunnen,
J.T. (2011). LOVD v.2.0: the next generation in gene variant databases. Hum. Mutat.
32, 557–563.
38. Cacciottolo, M., Belcastro, V., Laval, S., Bushby, K., di Bernardo, D., and Nigro, V.
(2011). Reverse engineering gene network identiﬁes new dysferlin-interacting pro-
teins. J. Biol. Chem. 286, 5404–5413.
39. Han, R., and Campbell, K.P. (2007). Dysferlin and muscle membrane repair. Curr.
Opin. Cell Biol. 19, 409–416.
40. Ono, H., Suzuki, N., Kanno, S., Izumi, R., Takahashi, T., Kitajima, Y., Osana, S.,
Akiyama, T., Ikeda, K., Shijo, T., et al. (2017). Novel binding partner of dysferlin is
required for plasma-membrane repair. Neuromuscul. Disord. 27 (Suppl 2 ), S146.
41. Matsuda, C., Kameyama, K., Tagawa, K., Ogawa, M., Suzuki, A., Yamaji, S., Okamoto,
H., Nishino, I., and Hayashi, Y.K. (2005). Dysferlin interacts with afﬁxin (beta-
parvin) at the sarcolemma. J. Neuropathol. Exp. Neurol. 64, 334–340.
42. Couet, J., Li, S., Okamoto, T., Ikezu, T., and Lisanti, M.P. (1997). Identiﬁcation of pep-
tide and protein ligands for the caveolin-scaffolding domain. Implications for the
interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272, 6525–
6533.
43. Galbiati, F., Volonte, D., Minetti, C., Bregman, D.B., and Lisanti, M.P. (2000). Limb-
girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitina-
tion and proteasomal degradation. Treatment with proteasomal inhibitors blocks604 Molecular Therapy: Nucleic Acids Vol. 13 December 2018the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveo-
lin-3. J. Biol. Chem. 275, 37702–37711.
44. Galbiati, F., Volonte, D., Minetti, C., Chu, J.B., and Lisanti, M.P. (1999). Phenotypic
behavior of caveolin-3 mutations that cause autosomal dominant limb girdle
muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within
the golgi complex. J. Biol. Chem. 274, 25632–25641.
45. Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E.,
Mazzocco, M., Egeo, A., Donati, M.A., et al. (1998). Mutations in the caveolin-3
gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18,
365–368.
46. Rothberg, K.G., Heuser, J.E., Donzell, W.C., Ying, Y.S., Glenney, J.R., and Anderson,
R.G. (1992). Caveolin, a protein component of caveolae membrane coats. Cell 68,
673–682.
47. Sargiacomo, M., Scherer, P.E., Tang, Z., Kübler, E., Song, K.S., Sanders, M.C., and
Lisanti, M.P. (1995). Oligomeric structure of caveolin: implications for caveolae
membrane organization. Proc. Natl. Acad. Sci. USA 92, 9407–9411.
48. Parton, R.G., Way, M., Zorzi, N., and Stang, E. (1997). Caveolin-3 associates with
developing T-tubules during muscle differentiation. J. Cell Biol. 136, 137–154.
49. Song, K.S., Scherer, P.E., Tang, Z., Okamoto, T., Li, S., Chafel, M., Chu, C., Kohtz,
D.S., and Lisanti, M.P. (1996). Expression of caveolin-3 in skeletal, cardiac, and
smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fraction-
ates with dystrophin and dystrophin-associated glycoproteins. J. Biol. Chem. 271,
15160–15165.
50. Scherer, P.E., and Lisanti, M.P. (1997). Association of phosphofructokinase-M with
caveolin-3 in differentiated skeletal myotubes. Dynamic regulation by extracellular
glucose and intracellular metabolites. J. Biol. Chem. 272, 20698–20705.
51. Aravamudan, B., Volonte, D., Ramani, R., Gursoy, E., Lisanti, M.P., London, B., and
Galbiati, F. (2003). Transgenic overexpression of caveolin-3 in the heart induces a
cardiomyopathic phenotype. Hum. Mol. Genet. 12, 2777–2788.
52. Williams, T.M., and Lisanti, M.P. (2004). The caveolin proteins. Genome Biol. 5, 214.
53. Wein, N., Avril, A., Bartoli, M., Beley, C., Chaouch, S., Laforêt, P., Behin, A., Butler-
Browne, G., Mouly, V., Krahn, M., et al. (2010). Efﬁcient bypass of mutations in dys-
ferlin deﬁcient patient cells by antisense-induced exon skipping. Hum. Mutat. 31,
136–142.
54. Takahashi, T., Aoki, M., Tateyama, M., Kondo, E., Mizuno, T., Onodera, Y., Takano,
R., Kawai, H., Kamakura, K., Mochizuki, H., et al. (2003). Dysferlin mutations in
Japanese Miyoshi myopathy: relationship to phenotype. Neurology 60, 1799–1804.
55. Takahashi, T., Aoki, M., Suzuki, N., Tateyama, M., Yaginuma, C., Sato, H., Hayasaka,
M., Sugawara, H., Ito, M., Abe-Kondo, E., et al. (2013). Clinical features and a muta-
tion with late onset of limb girdle muscular dystrophy 2B. J. Neurol. Neurosurg.
Psychiatry 84, 433–440.
